[go: up one dir, main page]

ATE309812T1 - Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie - Google Patents

Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie

Info

Publication number
ATE309812T1
ATE309812T1 AT03744873T AT03744873T ATE309812T1 AT E309812 T1 ATE309812 T1 AT E309812T1 AT 03744873 T AT03744873 T AT 03744873T AT 03744873 T AT03744873 T AT 03744873T AT E309812 T1 ATE309812 T1 AT E309812T1
Authority
AT
Austria
Prior art keywords
mutations
adenoviruses
genes
adenovirus
cancer therapy
Prior art date
Application number
AT03744873T
Other languages
English (en)
Inventor
Bonastre Ramon Alemany
Piqueras Manel Maria Cascallo
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE309812T1 publication Critical patent/ATE309812T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10364—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03744873T 2002-03-26 2003-03-25 Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie ATE309812T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200716 2002-03-26
PCT/ES2003/000140 WO2003080083A1 (es) 2002-03-26 2003-03-25 Uso de adenovirus mutados en los genes va para el tratamiento del cancer

Publications (1)

Publication Number Publication Date
ATE309812T1 true ATE309812T1 (de) 2005-12-15

Family

ID=27772025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744873T ATE309812T1 (de) 2002-03-26 2003-03-25 Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie

Country Status (14)

Country Link
US (3) US7344711B2 (de)
EP (2) EP1605053A1 (de)
JP (2) JP2005526099A (de)
AT (1) ATE309812T1 (de)
AU (1) AU2003226835B2 (de)
BR (1) BR0308634A (de)
CA (1) CA2478616C (de)
DE (1) DE60302350T2 (de)
DK (1) DK1498129T3 (de)
ES (1) ES2248764T3 (de)
HK (1) HK1071060A1 (de)
IL (2) IL163745A0 (de)
MX (1) MXPA04009204A (de)
WO (1) WO2003080083A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1498129T3 (da) * 2002-03-26 2006-04-03 Oncolytics Biotech Inc Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2007103825A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Combination therapy with oncolytic adenovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
ES2355882B1 (es) 2009-03-24 2012-02-13 INSTITUT CATALÀ D`ONCOLOGIA (Titular al 50%) Combinación de adenovirus oncolítico y un bloqueador de canal de calcio y su uso para el tratamiento del cáncer.
JPWO2012121071A1 (ja) * 2011-03-04 2014-07-17 国立大学法人大阪大学 ＶＡ−ＲＮＡｓが発現しないアデノウイルスベクター
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP2022543445A (ja) 2019-08-05 2022-10-12 メゾブラスト・インターナショナル・エスアーエールエル ウイルスベクターを含む細胞組成物及び処置方法
JP2023537103A (ja) 2020-08-10 2023-08-30 メゾブラスト・インターナショナル・エスアーエールエル 細胞組成物及び治療方法
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079159A (en) * 1983-12-27 1992-01-07 Genetics Institute, Inc. Method for making tissue plasminogen activator
JP2648301B2 (ja) * 1983-12-27 1997-08-27 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 真核細胞の形質転換のための補助ｄｎａを含むベクター
US5002874A (en) * 1987-09-17 1991-03-26 Genetics Institute, Inc. Genetically engineered eucaryotic host cells capable of expressing modified forms of eIF-2α
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
CA2388807C (en) * 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
CA2454992A1 (en) * 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
DK1498129T3 (da) * 2002-03-26 2006-04-03 Oncolytics Biotech Inc Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
WO2004050027A2 (en) * 2002-12-02 2004-06-17 Genvec, Inc. Materials and methods for treating ocular-related disorders

Also Published As

Publication number Publication date
ES2248764T3 (es) 2006-03-16
MXPA04009204A (es) 2004-11-26
US20060233753A1 (en) 2006-10-19
HK1071060A1 (en) 2005-07-08
JP2010184940A (ja) 2010-08-26
WO2003080083A1 (es) 2003-10-02
IL163745A (en) 2010-02-17
EP1498129B1 (de) 2005-11-16
BR0308634A (pt) 2005-02-15
US20090202489A2 (en) 2009-08-13
EP1605053A1 (de) 2005-12-14
JP2005526099A (ja) 2005-09-02
US20080089864A1 (en) 2008-04-17
DE60302350D1 (de) 2005-12-22
US20110053249A1 (en) 2011-03-03
DE60302350T2 (de) 2006-08-03
DK1498129T3 (da) 2006-04-03
US7344711B2 (en) 2008-03-18
AU2003226835B2 (en) 2006-11-09
EP1498129A1 (de) 2005-01-19
AU2003226835A1 (en) 2003-10-08
CA2478616C (en) 2012-05-29
CA2478616A1 (en) 2003-10-02
IL163745A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
ATE309812T1 (de) Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
EP2639319A3 (de) Psoriaseassoziierte genetische Polymorphien, Nachweisverfahren dafür und ihre Verwendung
DE602004017426D1 (de) Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2009039390A3 (en) The development of glycobiology-based therapeutics for the treatment of brain tumors
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2007058968A3 (en) Gene expression profiles and methods of use
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
AU2003293141A8 (en) Methods for identifying risk of breast cancer and treatments thereof
DK1390543T3 (da) Nye polynukleotider og polypeptider af IFNalfa-17-genet
WO2007120955A3 (en) Genes affecting human memory performance
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
NO20060420L (no) 2-aminobenzoylderivater
GB0300718D0 (en) Proteins
MXPA05008329A (es) Uso de un polimorfismo novedoso en el gen hsgk1 para el diagnostico de hipertonia y el uso de la familia del gen sgk en el diagnostico y terapia del sindrome q/t largo.
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
DE60222669D1 (de) Asthma-assoziiertes gen
ATE486286T1 (de) Prognoseverfahren für kongestives herzversagen
ATE498021T1 (de) Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1498129

Country of ref document: EP

REN Ceased due to non-payment of the annual fee